Michigan Institute for Neurological Disorders

Farmington Hills, Michigan 48335

0 studies enrolling now · 18 studies all time

What they study most

Alzheimer's Disease, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Muscle Spasticity, Parkinson´s Disease, Relapsing Multiple Sclerosis

Studies at this site

• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) — Running, not enrolling
• Rostock International Parkinson's Disease Study (ROPAD) — Completed
• ETNA-MS Device Validation Study — Completed
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis — Completed
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis — Completed
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — Completed
• An Adult Spasticity Registry of OnabotulinumtoxinA Treatment — Completed
• Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — NO_LONGER_AVAILABLE
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex — Completed
• Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis — Completed
• A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis — Completed
• Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects — Completed
• A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis — Completed
• Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis — Completed